Not explicitly Whenever possible GDG members should not have COI. No In some circumstances, a GDG may not be able to perform its work without members who have COIs, such as relevant clinical specialists who receive a substantial portion of their incomes from services pertinent to the CPG. True for KDIGO Members with COIs should represent not more than a minority of the GDG. No The chair or cochairs should not be a person(s) with COI. No Funders should have no role in CPG development. Yes 3. Guideline Development Group Composition 3.1 The GDG should be multidisciplinary and balanced, comprising a variety of methodological experts and clinicians, and populations expected to be affected by the CPG. Yes 3.2 Patient and public involvement should be facilitated by including (at least at the time of clinical question formulation and draft CPG review) a current or former patient, and a patient advocate or patient/consumer organization representative in the GDG. No 3.3 Strategies to increase effective participation of patient and consumer representatives, including training in appraisal of evidence, should be adopted by GDGs. No 4. Clinical Practice Guideline Systematic Review Intersection 4.1 Clinical practice guideline developers should use systematic reviews that meet standards set by the Institute of Medicine s Committee on Standards for Systematic Reviews of Comparative Effectiveness Research. Yes 4.2 When systematic reviews are conducted specifically to inform particular guidelines, the GDG and systematic review team should interact regarding the scope, approach, and output of both processes. Yes 5. 